Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 13/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176031 | 0.91 | P2RY6 (0.47) | P2RY6POLA1P2RY2P2RY4P2RY14 | |
| SCHEMBL2800175 | 0.83 | P2RY6 (0.58) | P2RY6POLA1P2RY2P2RY4P2RY14 | |
| SCHEMBL425422 | 0.83 | SLC28A1 (0.47) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL34463723 | 0.83 | P2RY14 (0.45) | P2RY6POLA1P2RY2P2RY4P2RY14 | |
| SCHEMBL607049 | 0.82 | POLA1 (0.60) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL18486630 | 0.81 | P2RY2 (0.48) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL32679517 | 0.80 | P2RY2 (0.45) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL11688927 | 0.80 | P2RY6 (0.45) | P2RY6POLA1P2RY2P2RY4P2RY14 | |
| SCHEMBL475344 | 0.80 | P2RY6 (0.51) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL3759574 | 0.79 | POLA1 (0.44) | P2RY6POLA1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8388966-B2 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20090004200-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060140962-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1372717-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002076499-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |